msd indonesia

What msd indonesia does

MSD Indonesia, operating as PT Merck Sharp & Dohme Indonesia, is the Indonesian subsidiary of Merck & Co., Inc. (NYSE: MRK), one of the world's largest biopharmaceutical companies. The company markets and distributes a portfolio of human medicines and vaccines in Indonesia, with a strategic focus on oncology and vaccines. Its product portfolio includes the NUSAGARD HPV vaccine, oncology therapeutics, and a broader vaccine and animal health lineup sourced from the parent company's global pipeline. Core technology assets include proprietary immuno-oncology platforms and recombinant HPV vaccine technology, the latter of which is the subject of an active technology transfer to Indonesia's state-owned Bio Farma for local manufacturing.

MSD Indonesia generates revenue primarily through government procurement channels, including national immunization programs such as BIAS (Bulan Imunisasi Anak Sekolah), and through sales to healthcare providers across the country. The company's go-to-market model relies on regulatory approvals from BPOM and WHO prequalification as prerequisites for participation in public tenders. Through its partnership with the Indonesian Ministry of Health, MSD Indonesia is positioned within the national cervical cancer elimination agenda and broader public health priorities.

The business model combines direct distribution of imported specialty pharmaceuticals with an emerging local manufacturing capability via Bio Farma. This dual structure is intended to reduce import dependency, improve cost competitiveness in government tenders, and deepen integration with Indonesia's public health infrastructure. Strategic partnerships with BPOM and Bio Farma serve as both regulatory and operational anchors, while the parent company's global R&D pipeline provides a continuous flow of new product introductions tailored to local disease burden priorities.

Name

msd indonesia

Legal name

Merck & Co., Inc.

Website

https://msd-indonesia.com

Company type

Public

Founded year

1891

Operating status

Operating

Short description

MSD Indonesia is the Indonesian subsidiary of Merck & Co., Inc., marketing oncology medicines, vaccines (including the NUSAGARD HPV vaccine), and animal health products. It serves the Indonesian government and healthcare providers through public-sector procurement and technology transfer partnerships with Bio Farma.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN)

akta.pro secondary industries

Funding, Reimbursement & Vaccines-for-Children (VFC)/Public Purchase Programs (HLAJAHAK), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM), Vaccines & Public Health Product Distribution (CRAOAHAI)

Keywords

• Biopharmaceutical research
• Oncology medicines
• Vaccine manufacturing
• HPV immunization
• Immuno-oncology therapies

Headquarters

HQ city

Jakarta

HQ country

Indonesia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceuticals: Sale of prescription medicines for treatment of various diseases including oncology, infectious diseases, cardio-metabolic disorders, and other therapeutic areas.
2. Vaccines: Development, manufacturing and distribution of vaccines including HPV vaccines, distributed through government programs and healthcare providers.
3. Animal Health: Veterinary medicines and services for prevention, treatment and control of disease in farm and companion animals.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

MSD Indonesia develops, markets, supplies and distributes prescription medicines and vaccines. Its product portfolio includes medicines for oncology, infectious diseases and cardio-metabolic disorders, as well as vaccines used through government programs and healthcare-provider channels.

Product overview

MSD Indonesia (PT Merck Sharp & Dohme Indonesia) operates as a research-intensive biopharmaceutical company established in 2005, focusing on two main therapeutic areas: oncology and vaccines. The product portfolio includes NUSAGARD (a locally manufactured 4-valent HPV vaccine developed through Bio Farma technology transfer), oncology medicines (with 400K+ patients treated and 1K+ clinical trials), and a broad range of vaccines for 20+ diseases. The company also maintains an Animal Health division and publishes the MSD Manuals medical reference. The business segments are Pharmaceuticals (oncology and other medicines), Vaccines, and Animal Health.

Differentiator

Problem solved

Functional benefit

Brands

• NUSAGARD: Locally manufactured 4-valent HPV vaccine launched in Indonesia in August 2023 through partnership between MSD and Bio Farma

Products and services

• NUSAGARD A locally manufactured 4-valent HPV vaccine developed through technology transfer from MSD to Bio Farma. It is Indonesia's first locally manufactured HPV vaccine and is designed to prevent cervical cancer.
• Oncology Medicines A portfolio of commercially available cancer-treatment medicines used by oncology providers. MSD reports that its oncology medicines have treated 400,000+ patients over the previous five years and that its cancer-medicine clinical-trial work has included 1,000+ trials across 30+ cancer types.
• Vaccines A portfolio of vaccines intended to protect against more than 20 potentially life-threatening diseases. MSD reports more than 130 years of discovering, developing, supplying and delivering vaccines.
• Animal Health Products Veterinary medicines and services for the prevention, treatment and control of disease across major farm and companion-animal species.

Quantifiable outcome

• Reached over 500 million people with innovations in 2022
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Six partnerships are on record, tiered flagship and core.

• Indonesian Ministry of HealthflagshipStrategic or Co-development Partner · 9 August 2023Collaboration with Indonesian Ministry of Health for expansion of national HPV immunization coverage through School Based Immunization (BIAS) Program. MSD supports the government's commitment to eliminate cervical cancer in Indonesia and WHO's global strategy for cervical cancer elimination.
• Cross-sector Professional OrganizationscoreStrategic or Co-development Partner · 9 August 2023MSD collaborates with the Ministry of Health and other cross-sector professional organizations to educate about cervical cancer and HPV immunization through Disease Awareness Program activities targeting medical workers, health workers and the general public.
• BPOM (Indonesian Drug and Food Control Agency)coreStrategic or Co-development Partner · 2 August 2023BPOM (Badan POM) provides regulatory support and oversight for locally manufactured vaccine NUSAGARD. The agency is committed to assisting Bio Farma in achieving end-to-end local production of the vaccine, from active substance manufacturing to finished products.
• Indonesian Ministry of State-Owned EnterprisescoreStrategic or Co-development Partner · 2 August 2023The Ministry of State-Owned Enterprises supports the Bio Farma-MSD partnership as part of Indonesia's health transformation plan and aspiration to become a global vaccine production hub.
• Bio FarmaflagshipStrategic or Co-development Partner · 13 December 2022MSD signed a framework agreement with Bio Farma (Indonesia's largest state-owned pharmaceutical holding with subsidiaries Kimia Farma and Indo Farma) for technology transfer to locally manufacture HPV vaccine. The partnership aims to increase domestic vaccine manufacturing capabilities and capacity in Indonesia. Bio Farma operates from headquarters covering 91,058 square meters in Bandung with production capacity of more than 3.2 billion vaccine doses per year.
• MSD-Wellcome Trust Hilleman LaboratoriescoreStrategic or Co-development PartnerPartnership engaged with the global health community through Hilleman Laboratories, pursuing innovation in vaccine science and technology to make vaccines more affordable and equitable in lower-income markets.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• GSK Indonesia: GlaxoSmithKline's Indonesian subsidiary markets vaccines (including HPV competitor Cervarix) and pharmaceuticals. Direct competitor to MSD in Indonesia's national HPV tenders and broader pharma market.
• Pfizer Indonesia: Pfizer's Indonesian subsidiary markets vaccines and a broad oncology/primary-care portfolio. Competes head-to-head with MSD for national immunization contracts and oncology market share in Indonesia.
• Sanofi Indonesia: Sanofi's Indonesian arm sells vaccines and specialty pharmaceuticals, including pediatric and travel vaccines. Competes with MSD for government tenders and private-channel vaccine sales in Indonesia.
• Roche Indonesia: Roche's Indonesian subsidiary markets oncology and immunology medicines. Direct competitor to MSD in oncology, particularly in breast and lung cancer segments.
• AstraZeneca Indonesia: AstraZeneca's Indonesian operation markets oncology, respiratory, and vaccine products. Competes with MSD across oncology indications and has been active in Indonesia's HPV and COVID immunization programs.
• Novartis Indonesia: Novartis's Indonesian arm sells specialty pharmaceuticals including oncology. Competes with MSD's oncology portfolio in Indonesian hospitals and through physician channels.
• Johnson & Johnson Indonesia: J&J's Indonesian subsidiary markets pharmaceuticals and vaccines, including oncology assets. Comparable multinational pharma footprint in Indonesia targeting hospitals and government channels.

Emerging players

• Bio Farma: Indonesia's state-owned vaccine producer and MSD's local manufacturing partner. Overlaps with MSD in vaccine manufacturing and increasingly competes in HPV and other vaccine tenders.
• Sinovac Biotech: Chinese vaccine manufacturer that supplied COVID-19 vaccines to Indonesia via Bio Farma and competes in regional vaccine tenders. Emerging threat in Indonesia's broader immunization procurement.

Regional players

• Takeda Indonesia: Takeda's Indonesian operation markets vaccines, oncology, and specialty care products. Comparable multinational pharma and vaccine footprint competing for hospital and government share in Indonesia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/MSDInvents
• YouTubeyoutube.com/channel/UChHvXY_b3cgM_Bvb2J-B5-Q
• Facebookfacebook.com/MSDInvents
• LinkedInlinkedin.com/company/msd-global
• Instagraminstagram.com/msdinvents

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about msd indonesia